Literature DB >> 25000947

Erythrocyte phosphatidylserine exposure in β-thalassemia.

Hamdy A Ibrahim1, Manal I Fouda2, Raida S Yahya3, Nashwa K Abousamra2, Rania A Abd Elazim3.   

Abstract

[ABS]Phospholipid asymmetry is well maintained in erythrocyte (RBC) membranes with phosphatidylserine (PS) exclusively present in the inner leaflet. Eryptosis, the suicidal death of RBCs, is characterized by cell shrinkage, membrane blebbing, and cell membrane phospholipids scrambling with PS exposure at the cell surface. Erythrocytes exposing PS are recognized, bound, engulfed, and degraded by macrophages. Eryptosis thus fosters clearance of affected RBCs from circulating blood, which may aggravate anemia in pathological conditions. Thalassemia patients are more sensitive to the eryptotic depletion and osmotic shock which may affect RBC membrane phospholipid asymmetry. We aimed in this work to determine the RBC PS exposure in splenectomized and nonsplenectomized β-thalassemia major (β-TM) patients and correlate it with the clinical presentation and laboratory data. RBCs were stained for annexin V to detect phosphatidylserine (PS) exposure in 46 β-TM patients (27 splenectomized and 19 nonsplenectomized) compared to 17 healthy subjects as a control group. We observed a significant increase in RBC PS exposure in β-TM patients compared to control group (P = .0001). Erythrocyte PS exposure was significantly higher in splenectomized β-TM patients compared with nonsplenectomized β-TM patients (P = .001). No correlation was found between RBC PS exposure and clinical or hematological data of β-TM patients, but there was a positive correlation between RBC PS exposure and ferritin level in β-TM patients have higher levels of RBC PS exposure, and splenectomy was shown to aggravate RBC PS exposure without aggravation of anemia.

Entities:  

Keywords:  Annexin V; Flow Cytometry; Phosphatidylserine; RBCs; Thalassemia

Mesh:

Substances:

Year:  2014        PMID: 25000947     DOI: 10.1532/LH96.12016

Source DB:  PubMed          Journal:  Lab Hematol        ISSN: 1080-2924


  9 in total

Review 1.  Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.

Authors:  Stefano Rivella
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

Review 2.  Host genetics in malaria: lessons from mouse studies.

Authors:  Hong Ming Huang; Brendan J McMorran; Simon J Foote; Gaetan Burgio
Journal:  Mamm Genome       Date:  2018-03-28       Impact factor: 2.957

Review 3.  Red blood cells: the forgotten player in hemostasis and thrombosis.

Authors:  J W Weisel; R I Litvinov
Journal:  J Thromb Haemost       Date:  2019-01-07       Impact factor: 5.824

4.  Role of red blood cells in haemostasis and thrombosis.

Authors:  Rustem I Litvinov; John W Weisel
Journal:  ISBT Sci Ser       Date:  2016-12-14

5.  The Correlation Between Ineffective Erythropoiesis Biomarkers and Development of Extramedullary Hematopoiesis in Patients with Thalassemia.

Authors:  Siriyakorn Chansai; Supawadee Yamsri; Supan Fucharoen; Goonnapa Fucharoen; Nattiya Teawtrakul
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-07-01       Impact factor: 3.122

Review 6.  Redox Balance in β-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship.

Authors:  Rayan Bou-Fakhredin; Lucia De Franceschi; Irene Motta; Assaad A Eid; Ali T Taher; Maria Domenica Cappellini
Journal:  Antioxidants (Basel)       Date:  2022-05-13

7.  The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major.

Authors:  Ayşegül Uğur Kurtoğllu; Belkıs Koçtekin; Erdal Kurtoğlu; Mustafa Yildiz
Journal:  Arch Med Sci       Date:  2018-12-30       Impact factor: 3.318

Review 8.  Eryptosis: Programmed Death of Nucleus-Free, Iron-Filled Blood Cells.

Authors:  Peter Dreischer; Michael Duszenko; Jasmin Stein; Thomas Wieder
Journal:  Cells       Date:  2022-02-01       Impact factor: 6.600

Review 9.  Oxidative stress in β-thalassaemia and sickle cell disease.

Authors:  S Voskou; M Aslan; P Fanis; M Phylactides; M Kleanthous
Journal:  Redox Biol       Date:  2015-08-01       Impact factor: 11.799

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.